Pancreatic/Thyroid/Other Endocrine Cancers

Prognostic Survival Model Developed for Treatment of Urothelial Cancer

February 09, 2018

"We believe we've developed the first prognostic model that, once confirmed in larger studies, could provide a critical decision-making tool for clinicians," said lead author Gregory Russell Pond, PhD.

Atezolizumab + Bevacizumab vs. Sunitinib in Met Renal CA

February 09, 2018

The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.

Lutathera Approved for Gastroenteropancreatic Neuroendocrine Tumors

By January 26, 2018

Lutathera is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Azedra Under FDA Review for Rare Neuroendocrine Tumors

By January 02, 2018

Azedra, a high-specific-activity radiotherapeutic product, is a substrate for the norepinephrine reuptake transporter that is highly expressed on the cell surface of neuroendocrine tumors.

First Dose-Escalation Study Examines Ulixertinib for Advanced Tumors

December 18, 2017

The researchers found that ulixertinib exposure was dose-proportional to the RP2D and almost completely inhibited ERK activity in whole blood.

Erlotinib Overdose May Lead to Rapid Onset of Ocular Toxicity

November 17, 2017

Findings in case study of man being treated for non-small-cell lung cancer

First-in-Class, Oral Agent Gets Orphan Drug Status for Pancreatic Cancer

By October 20, 2017

Mesupron is a first-in-class, orally-administered protease inhibitor.

'Widely Divergent' Beliefs Across U.S. Regarding Thyroid Nodules, CA

October 13, 2017

There was a 6.2-fold difference in thyroidectomy rates across U.S. regions (range, 22 to 139 per 100,000 Medicare beneficiaries).

Handheld Pen Device Rapidly Detects Cancerous Tissue

By September 08, 2017

Researchers at the University of Texas, who developed the MasSpec Pen device, tested its capability on 20 thin tissue sections (including breast tissues, thyroid tissues, papillary thyroid carcinoma, and follicular thyroid adenoma tissues) and 253 human patient tissue samples (including lung, ovary, thyroid and breast samples) some normal and some cancerous.

Androgen-Deprivation Therapy and CVD: What's the Link?

August 29, 2017

The researchers found that the men with early-stage prostate cancer who did not already have cardiovascular disease, but who received ADT had an 81% higher risk for heart failure.

Underlying Mechanisms ID'd in Curcumin Resensitization of CA Cells

August 02, 2017

The researchers reported the resensitization of chemoresistant PDAC cells by curcumin through inhibition of the PRC2-PVT1-c-Myc axis.

First-in-Class Pancreatic Cancer Drug Gains Orphan Drug Status

By June 21, 2017

Clinical trials of pamrevlumab are currently ongoing for conditions such as idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy.

USPSTF Issues Recommendation on Thyroid Cancer Screening

May 10, 2017

U.S. Preventive Services Task Force reaffirms guidelines it issued in 1996 and 2016

ASCO: Pancreatic Cancer Treatment Update

April 17, 2017

Regimen of gemcitabine, capecitabine preferred in absence of concerns for toxicity, tolerance

Massage Improves Pain, Lymphedema in Female CA Patients

March 10, 2017

The researchers found that all participants reported a positive experience with aromatherapy massage.

Xermelo Approved for Carcinoid Syndrome Diarrhea

By March 01, 2017

That FDA has approved Xermelo (telotristat ethyl) tablets as the first oral treatment for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Regular Aspirin Use May Reduce Pancreatic Cancer Risk

December 21, 2016

Regular aspirin use is associated with reduced risk of pancreatic cancer in a Chinese cohort, according to a study published online in Cancer Epidemiology, Biomarkers & Prevention.

USPSTF Issues Statement on Thyroid Cancer Screening

November 23, 2016

Widespread routine thyroid cancer screening can lead to overdiagnosis, overtreatment

Do NSAIDs, Statins Reduce Pancreatic Cancer Risk?

By November 09, 2016

Findings from previous studies have been conflicting.

Linear Relation Between Age and Survival in Papillary Thyroid Cancer

November 02, 2016

For patients with papillary thyroid cancer (PTC), patient age is associated with death in a linear fashion, with no apparent age cut point demarcating survival difference, according to a study published online in the Journal of Clinical Oncology.

Metformin Tied to Increased Survival in Pancreatic CA Patients

By July 27, 2016

For pancreatic ductal adenocarcinoma (PDAC) patients with diabetes, metformin treatment was associated with an increase in survival. Those were the findings of a new study published in the American Journal of Gastroenterology.

Vitamin D Levels Tied to Survival in Pancreatic Cancer

June 22, 2016

Longer overall survival for patients with sufficient prediagnostic 25-hydroxyvitamin D

FDA Designates Selumetinib Orphan Drug for Differentiated Thyroid CA

By May 17, 2016

AstraZeneca announced that the FDA has granted Orphan Drug designation to selumetinib for the adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC).

OTC Anti-Radiation Drug Gets FDA Approval

By May 17, 2016

Mission Pharmacal announced that the Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for over-the-counter liquid Potassium Iodide Oral Solution for use in the event of a nuclear emergency.

Study Tests Additional Tx for Improving Survival in Advanced Pancreatic Cancer

May 04, 2016

Neither extra chemotherapy drug nor add-on radiation aided longevity in French trial

Cancer Deaths Declining by 1.5% a Year in the U.S.

March 10, 2016

Overall rates of cancer and cancer mortality in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer.

Afinitor Receives Additional FDA Approval

By February 26, 2016

Novartis' Afinitor (everolimus) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease.

Concerns Over Incretin-Based Drugs, Pancreatic Cancer Risk Addressed in New Study

By February 22, 2016

A new international, multicenter study has found that incretin-based drugs, used to treat type 2 diabetes, are not associated with an increased risk of pancreatic cancer.

Thyroid CA Patients Report Poor QOL, Despite Good Prognoses

December 29, 2015

Quality of life lower than that seen among survivors of colorectal, breast, and other types of cancer

Burden, Costs of Gastrointestinal, Liver Disease Estimated in U.S.

December 02, 2015

GI hemorrhage is most common diagnosis leading to hospitalization, with cost of 5 billion in 2012